Get the Stockscreener App
8.89
3.86%
+0.33
Acrivon Therapeutics Inc stock is currently priced at $8.89, with a 24-hour trading volume of 57,841.
It has seen a +3.86% increased in the last 24 hours and a -14.02% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $8.61 pivot point. If it approaches the $8.97 resistance level, significant changes may occur.
Previous Close:
$8.56
Open:
$8.57
24h Volume:
57,841
Market Cap:
$274.50M
Revenue:
-
Net Income/Loss:
$-60.39M
P/E Ratio:
-3.5574
EPS:
-2.499
Net Cash Flow:
$-43.93M
1W Performance:
+1.37%
1M Performance:
-14.02%
6M Performance:
+128.53%
1Y Performance:
-34.15%
1D Range:
$8.565
$9.00
52W Range:
$3.19
$14.03
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Name
Acrivon Therapeutics Inc
Sector
Industry
Phone
617 207 8979
Address
480 Arsenal Way, Suite 100, Watertown
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Apr-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Apr-20-23 | Initiated | H.C. Wainwright | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Dec-12-22 | Initiated | Jefferies | Buy |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
View All
Acrivon Therapeutics Inc Stock (ACRV) Latest News
Acrivon Therapeutics, Inc. to Post Q2 2024 Earnings of ($0.48) Per Share, HC Wainwright Forecasts (NASDAQ:ACRV) - Defense World
Defense World
JMP Securities Initiates Coverage of Acrivon Therapeutics (ACRV) with Market Outperform Recommendation - MSN
MSN
Acrivon Therapeutics, Inc. to Post Q2 2024 Earnings of ($0.48) Per Share, HC Wainwright Forecasts (NASDAQ:ACRV) - MarketBeat
MarketBeat
Acrivon Therapeutics (NASDAQ:ACRV) Rating Reiterated by BMO Capital Markets - Defense World
Defense World
Acrivon Therapeutics reports Q1 EPS (73c), consensus (84c) - TipRanks.com - TipRanks
TipRanks
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $22.88 Average Target Price from Analysts - MarketBeat
MarketBeat
Acrivon Therapeutics Inc Stock (ACRV) Financials Data
Acrivon Therapeutics Inc (ACRV) Net Income 2024
ACRV net income (TTM) was -$60.39 million for the quarter ending December 31, 2023, a -93.76% decrease year-over-year.
Acrivon Therapeutics Inc (ACRV) Cash Flow 2024
ACRV recorded a free cash flow (TTM) of -$43.93 million for the quarter ending December 31, 2023, a -36.07% decrease year-over-year.
Acrivon Therapeutics Inc (ACRV) Earnings per Share 2024
ACRV earnings per share (TTM) was -$2.74 for the quarter ending December 31, 2023, a -19.18% decline year-over-year.
Acrivon Therapeutics Inc Stock (ACRV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chione Ltd | 10% Owner |
Jun 26 '23 |
Sale |
12.93 |
16 |
207 |
3,848,632 |
| Holm-Jorgensen Rasmus | Chief Financial Officer |
Jun 16 '23 |
Option Exercise |
3.63 |
9,500 |
34,485 |
29,530 |
| Chione Ltd | 10% Owner |
Jun 15 '23 |
Sale |
12.14 |
2,056 |
24,960 |
3,848,648 |
| Chione Ltd | 10% Owner |
Jun 14 '23 |
Sale |
12.13 |
893 |
10,832 |
3,850,704 |
| Chione Ltd | 10% Owner |
Jun 13 '23 |
Sale |
12.30 |
3,000 |
36,900 |
3,851,597 |
| Chione Ltd | 10% Owner |
Jun 12 '23 |
Sale |
12.34 |
2,000 |
24,680 |
3,854,597 |
| Devroe Eric | Chief Operating Officer |
Jun 05 '23 |
Option Exercise |
1.04 |
9,225 |
9,594 |
62,883 |
| Blume-Jensen Peter | President and CEO |
May 31 '23 |
Option Exercise |
3.88 |
33,605 |
130,387 |
2,403,702 |
About Acrivon Therapeutics Inc
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to specific medicine by utilizing its proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3). The AP3 platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients predicted to benefit from its drug candidates. The company's lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, is being advanced in a potentially registrational Phase 2 trial across various tumor types. It is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1 and PKMYT1. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
0.77%
1.20%
Cap:
|
Volume (24h):